Director/PDMR Shareholding

ReNeuron Group plc
07 January 2008

PRESS RELEASE



Director share purchases



Guildford, UK, 7 January 2008: ReNeuron Group plc (LSE: RENE.L) was advised
today of the following purchases of Ordinary shares in the Company by directors
of the Company:-




Director                                       Number of shares purchased and         Total shareholding after
                                                              price per share                         purchase
Professor Trevor Jones (Chairman)                             28,000 at 17.8p                          111,200
Michael Hunt (Chief Executive Officer)                       33,000 at 18.38p                          237,113
Dr John Sinden (Chief Scientific Officer)                    28,328 at 17.65p                        1,395,913
Mark Docherty (Non-executive Director                         28,000 at 17.8p                          174,400
Dr Paul Harper (Non-executive Director)                     27,600 at 18.025p                          110,800





Enquiries:


ReNeuron
Michael Hunt, Chief Executive Officer                    Tel: [phone]


Financial Dynamics
Europe
David Yates                                             Tel: [phone]
Lara Mott
US
Robert Stanislaro                                       Tel : [phone]





About ReNeuron



ReNeuron is a leading, UK-based stem cell therapy business.  It is applying its
novel stem cell platform technologies in the development of ground-breaking stem
cell therapies to serve significant and unmet or poorly-met clinical needs.  The
Company operates from laboratories in Surrey, UK and Los Angeles, California,
USA.



ReNeuron has used its c-mycER technology to generate genetically stable neural
stem cell lines.  This technology platform has multi-national patent protection
and is fully regulated by means of a chemically-induced safety switch.  Cell
growth can therefore be completely arrested prior to in vivo implantation.



ReNeuron has filed for approval to commence initial clinical studies in the US
with its lead ReN001 stem cell therapy for chronic stroke disability.  There are
an estimated 50 million stroke survivors worldwide, approximately one half of
which are left with permanent disabilities.  The annual health and social costs
of caring for these patients is estimated to be in excess of £5 billion in the
UK and in excess of US$50 billion in the US.



In addition to its stroke programme, ReNeuron is developing stem cell therapies
for Parkinson's disease, Huntington's disease, Type 1 diabetes and diseases of
the retina.  The Company recently announced the acquisition of the business
assets of AmCyte Inc. in the US, bringing clinically-tested cell encapsulation
technology to ReNeuron's ReN002 diabetes programme.



ReNeuron has leveraged its stem cell technologies into non-therapeutic areas -
its ReNcell(R) range of cell lines for use in research and in drug discovery
applications in the pharmaceutical industry.  ReNeuron's ReNcell(R)CX and
ReNcell(R)VM neural cell lines are marketed worldwide under license by Millipore
Corporation.



ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.



Further information on ReNeuron and its products can be found at
www.reneuron.com.



Data sources: UK Stroke Association; American Stroke Association.



This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements




                      This information is provided by RNS
            The company news service from the London Stock Exchange